Stay updated on Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page.

Latest updates to the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2; no visible changes to study details, layout, or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedThe page revision updated from v3.4.0 to v3.4.1, with no substantive changes to trial details, eligibility, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedA minor revision update from v3.3.3 to v3.3.4 is displayed on the page, with no observed changes to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check70 days agoChange DetectedThe page now includes a Locations section with North Carolina listed as a location. The old 'North Carolina Locations' entry and 'HHS Vulnerability Disclosure' link were removed, and the revision is updated to v3.3.3.SummaryDifference0.2%

- Check99 days agoChange DetectedThe page revision was updated from v3.2.0 to v3.3.2 with no visible changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check107 days agoChange DetectedThe page removes a general government funding status notice; the study content and enrollment details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page.